Biogen Inc

NASDAQ: BIIB
$166.83
+$1.04 (+0.6%)
Real Time Data Delayed 15 Min.

BIIB Articles

Shares of Ionis Pharmaceuticals and Biogen were on the move Monday morning after the companies announced positive interim results from a late-stage trial.
Biogen reported better-than-expected third-quarter financial results before the markets opened on Wednesday,
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood out from the rest with at least 25% gains.
Shares of Anavex Life Sciences soared on Wednesday following a material transfer agreement with Biogen.
The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
The August 31 short interest data have been compared with the previous report, and short interest decreased for most of these selected biotech stocks.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Biogen, Broadcom, Devon Energy, Gilead Sciences, Mondelez and Urban Outfitters.
The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.
Investors are now focusing on fundamentals and near-term catalysts that could provide a tailwind for some of the biotech leaders.
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.